PRODUCTS & SERVICES
MultiplexDX joined the Cancer and Metabolic Disorders conference organized by The Alliance4Life consortium, a bottom-up initiative of 12 leading life science institutions from eleven EU-13countries that aims to bridge the health research and innovation gap between European countries, especially in Central and Eastern Europe.
We were delighted to meet our colleagues and friends and our Chief Scientific Officer, Evan Paul, presented the latest findings from our EIC Accelerator grant, which aims to validate ourMultiplex8+ test for breast cancer.
Prof. Pawel Swietach from the University of Oxford delivered the keynote lecture about his research on how biological processes are affected by chemical acidity.
The program of this mini-conference covered the top priorities of the Horizon Europe Cancer Mission, including scientific lectures, project opportunities, and matchmaking between academia and industry.
Since research and innovation performance is unevenly distributed across the EU, conferences like this help foster collaboration of scientists on the international level and across the region and play a vital role in strengthening the ecosystem.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.